$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000101749117000074 Filed on May 11, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$0.00	$0.00	$626.0K
YoY Change	-100.0%	-100.0%	31.79%
Cost Of Revenue			$233.0K
YoY Change			0.0%
Gross Profit			$393.0K
YoY Change			62.4%
Gross Profit Margin			62.78%
Selling, General & Admin	$1.600M	$1.440M	$2.220M
YoY Change	-24.53%	-35.14%	-28.39%
% of Gross Profit			564.89%
Research & Development	$839.0K	$412.0K	$2.602M
YoY Change	-66.48%	-84.17%	-20.38%
% of Gross Profit			662.09%
Depreciation & Amortization	$20.00K	$56.00K	$72.00K
YoY Change	-75.0%	-22.22%	-2.7%
% of Gross Profit			18.32%
Operating Expenses	$2.441M	$1.853M	$4.826M
YoY Change	-47.22%	-61.6%	-24.17%
Operating Profit	-$2.441M	-$1.853M	-$4.826M
YoY Change	-47.22%	-61.6%	-21.17%
Interest Expense	$3.000K	-$95.00K	-$279.0K
YoY Change	-101.16%	-65.95%	76.58%
% of Operating Profit
Other Income/Expense, Net	$719.0K	-$1.551M	$2.312M
YoY Change	-47.59%	-167.08%	-897.24%
Pretax Income	-$1.720M	-$3.400M	-$2.510M
YoY Change	-47.08%	35.46%	-60.84%
Income Tax			$4.000K
% Of Pretax Income
Net Earnings	-$1.474M	$8.073M	-$2.505M
YoY Change	-55.84%	-422.28%	-60.93%
Net Earnings / Revenue			-400.16%
Basic Earnings Per Share		$1.04	-$0.46
Diluted Earnings Per Share	-$3.868M	$1.04	-$0.95
COMMON SHARES
Basic Shares Outstanding	12.77M shares	7.737M shares	5.505M shares
Diluted Shares Outstanding		7.737M shares	5.602M shares

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.820M	$3.760M	$6.910M
YoY Change	187.5%	-45.59%	-57.24%
Cash & Equivalents	$7.821M	$3.762M	$6.907M
Short-Term Investments
Other Short-Term Assets	$830.0K	$1.380M	$1.120M
YoY Change	12.16%	23.21%	-2.61%
Inventory			$405.0K
Prepaid Expenses
Receivables			$688.0K
Other Receivables			$0.00
Total Short-Term Assets	$8.649M	$5.146M	$9.119M
YoY Change	75.61%	-43.57%	-49.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$121.0K	$142.0K	$1.235M
YoY Change	-89.6%	-88.5%	-14.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$45.00K	$65.00K	$78.00K
YoY Change	-42.31%	-16.67%	-49.02%
Total Long-Term Assets	$166.0K	$207.0K	$1.313M
YoY Change	-86.62%	-84.23%	-18.04%
TOTAL ASSETS
Total Short-Term Assets	$8.649M	$5.146M	$9.119M
Total Long-Term Assets	$166.0K	$207.0K	$1.313M
Total Assets	$8.815M	$5.353M	$10.43M
YoY Change	42.96%	-48.69%	-46.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$140.0K	$490.0K	$1.100M
YoY Change	-91.25%	-55.45%	25.0%
Accrued Expenses	$716.0K	$545.0K	$2.902M
YoY Change	-73.99%	-81.22%	-42.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$8.750M
YoY Change	-100.0%	-100.0%	1550.94%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.844M	$2.590M	$13.25M
YoY Change	-86.1%	-80.45%	85.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$60.00K	$67.00K	$179.0K
YoY Change	-54.2%	-62.57%	-40.73%
Total Long-Term Liabilities	$60.00K	$67.00K	$179.0K
YoY Change	-54.2%	-62.57%	-40.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.844M	$2.590M	$13.25M
Total Long-Term Liabilities	$60.00K	$67.00K	$179.0K
Total Liabilities	$2.243M	$4.511M	$17.28M
YoY Change	-85.63%	-73.89%	-3.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$309.7M	-$308.2M	-$311.4M
YoY Change	-1.59%	-1.01%	5.1%
Common Stock	$316.3M	$309.1M	$304.5M
YoY Change	3.6%	1.49%	2.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.572M	$842.0K	-$6.843M
YoY Change
Total Liabilities & Shareholders Equity	$8.815M	$5.353M	$10.43M
YoY Change	42.96%	-48.69%	-46.88%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$1.474M	$8.073M	-$2.505M
YoY Change	-55.84%	-422.28%	-60.93%
Depreciation, Depletion And Amortization	$20.00K	$56.00K	$72.00K
YoY Change	-75.0%	-22.22%	-2.7%
Cash From Operating Activities	-$2.270M	-$2.700M	-$6.122M
YoY Change	-29.72%	-55.9%	-0.08%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$6.000K
YoY Change	-100.0%	-100.0%	-96.36%
Acquisitions
YoY Change
Other Investing Activities	$250.0K	$11.50M	$100.0K
YoY Change	38.89%	11400.0%
Cash From Investing Activities	$250.0K	$11.50M	-$6.000K
YoY Change	47.06%	-191766.67%	-96.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$9.947M
YoY Change		-100.0%	-9.22%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.080M	-7.130M	$9.148M
YoY Change	-647.75%	-177.94%	-17.2%
NET CHANGE
Cash From Operating Activities	-2.270M	-2.700M	-$6.122M
Cash From Investing Activities	250.0K	11.50M	-$6.000K
Cash From Financing Activities	6.080M	-7.130M	$9.148M
Net Change In Cash	4.060M	1.670M	$3.020M
YoY Change	-197.36%	-44.7%	-36.5%
FREE CASH FLOW
Cash From Operating Activities	-$2.270M	-$2.700M	-$6.122M
Capital Expenditures	$0.00	$0.00	$6.000K
Free Cash Flow	-$2.270M	-$2.700M	-$6.128M
YoY Change	-29.5%	-55.94%	-2.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
CY2016Q3	apri	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P5Y6M
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
CY2017Q1	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
CY2017Q1	apri	Expected Payments Received For Delivery Of Product Related Inventory ExpectedPaymentsReceivedForDeliveryOfProductRelatedInventory	709000	USD
CY2017Q1	apri	Expected Payments Received For Transition Services ExpectedPaymentsReceivedForTransitionServices	500000	USD
CY2016Q1	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
CY2017Q1	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
CY2016Q1	apri	Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Amount NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationAmount	137000	USD
CY2017Q1	apri	Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Amount NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationAmount	0	USD
CY2017Q1	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2016Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	142000	USD
CY2017Q1	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	11000	USD
CY2017Q1	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	100000	USD
CY2017Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm	P4Y9M7D
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
CY2017Q1	dei	Trading Symbol TradingSymbol	APRI
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	686000	USD
CY2017Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	485000	USD
CY2016Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	98000	USD
CY2016	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P4Y7M10D
CY2017Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermOne	P4Y9M7D
CY2016Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2017Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	2070932	shares
CY2017Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.74
CY2016Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	15.19
CY2017Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.74
CY2017Q1	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	52.50
CY2017Q1	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	74100000	USD
CY2014Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
CY2016Q3	apri	Stock Sale Restriction Period StockSaleRestrictionPeriod	P90D
CY2017Q1	apri	Working Capital WorkingCapital	2600000	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12771782	shares
CY2017Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	614000	USD
CY2017Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	738000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1236000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	545000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	783000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	315000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	308784000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	309069000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	285000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	355000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	284000	USD
CY2016Q4	us-gaap	Assets Assets	4700000	USD
CY2017Q1	us-gaap	Assets Assets	5353000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3634000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	5146000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1370000	USD
CY2017Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1203000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6907000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3762000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3020000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1675000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2017Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	11500000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1200000	USD
CY2017Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1504000	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.75	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2070932	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7733205	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7741782	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7733205	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7741782	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2016Q1	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	100000	USD
CY2017Q1	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	0	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	134000	USD
CY2017Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	90000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	72000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	56000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	846000	USD
CY2017Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1854000	USD
CY2017Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1900000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2016Q1	us-gaap	Dilutive Securities DilutiveSecurities	-2800000	USD
CY2017Q1	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2017Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	11817000	USD
CY2016Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0.00
CY2017Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	1.48
CY2016Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.00
CY2017Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	1.48
CY2016Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	842000	USD
CY2017Q1	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2017Q1	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12209000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2800000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1008000	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2224000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1441000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2514000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3404000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.46
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.44
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.95
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.44
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	9000	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11477000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-202000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-171000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	479000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-569000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	124000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-45000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-196000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	25000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-7000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-237000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-279000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-95000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	185000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	92000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12216000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	4511000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4700000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5353000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11294000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2590000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2108000	USD
CY2017Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	822000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-1200000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	9996000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9191000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-7129000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	94000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5065000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1192000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-2505000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	8073000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	8100000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5314000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3404000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2312000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1551000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6650000	USD
CY2017Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	4826000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	1853000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4826000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1853000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	177000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	129000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	65000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	67000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2016Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3200000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	177000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9947000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7800000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3700000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9600000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	142000	USD
CY2016Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	205000	USD
CY2017Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2016Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	755000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2602000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	412000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316308000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308235000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	355000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	284000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0157
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	246914	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2317846	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2070932	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.60
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	415000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	407000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.23
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.27
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.23
CY2016Q1	us-gaap	Stock Issued1 StockIssued1	249000	USD
CY2017Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-7516000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	842000	USD
CY2016Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1700000	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	97000	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5602000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7737000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5505000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7737000	shares

Files In Submission

Name	View Source	Status
0001017491-17-000074-index-headers.html	Edgar Link	pending
0001017491-17-000074-index.html	Edgar Link	pending
0001017491-17-000074.txt	Edgar Link	pending
0001017491-17-000074-xbrl.zip	Edgar Link	pending
apri-20170331.xml	Edgar Link	completed
apri-20170331.xsd	Edgar Link	pending
apri-20170331_cal.xml	Edgar Link	unprocessable
apri-20170331_def.xml	Edgar Link	unprocessable
apri-20170331_lab.xml	Edgar Link	unprocessable
apri-20170331_pre.xml	Edgar Link	unprocessable
apri3311710q.htm	Edgar Link	pending
apri33117ex311.htm	Edgar Link	pending
apri33117ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2017 Q2 Form 10-Q Financial Statement

#000101749117000074 Filed on May 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2017 Q2 Form 10-Q Financial Statement

#000101749117000074 Filed on May 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel